Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus

Arthritis Care and Research

Volumn 62, Issue 3, 2010, Pages 386-392

  Schmajuk, Gabriela ^a   Yazdany, Jinoos ^b   Trupin, Laura ^b   Yelin, Edward ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PREVALENCE; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIRHEUMATIC AGENTS; CALIFORNIA; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INTERVIEWS AS TOPIC; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS;

EID: 77649209443     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20002     Document Type: Article

References (27)

1. Wallace DJ. Antimalarials: the 'real' advance in lupus. Lupus 2001;10:385-7.
2. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401-4.
3. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al, and the Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998;7:80-5.
4. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006;15: 366-70.
5. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 1:S16-22.
6. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68:238-41.
7. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007;298:187-93.
8. Fessler BJ, Alarcon GS, McGwin G, Roseman J, Bastian HM, Friedman AW, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
9. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83.
10. Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus: prospective long-term study of an Israeli cohort. Lupus 2002;11:356-61.
11. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72.
12. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2009. E-pub ahead of print.
13. Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008;17:271-3.
14. Fernandez M, McGwin G Jr, Bertoli AM, Calvo-Alen J, Vila LM, Reveille JD, et al. Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). Lupus 2006;15:700-4.
15. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308.
16. Molina MJ, Mayor AM, Franco AE, Morell CA, Lopez MA, Vila LM. Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis 2008;18 Suppl 2:S205-10.
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7.
18. Karlson EW, Daltroy LH, Rivest C, Ramsey-Goldman R, Wright EA, Partridge AJ, et al. Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003;12:280-6.
19. Yazdany J, Yelin EH, Panopalis P, Trupin L, Julian L, Katz PP. Validation of the Systemic Lupus Erythematosus Activity Questionnaire in a large observational cohort. Arthritis Rheum 2008;59:136-43.
20. Cohen JW, Monheit AC, Beauregard KM, Cohen SB, Lefkowitz DC, Potter DE, et al. The Medical Expenditure Panel Survey: a national health information resource. Inquiry 1996-1997; 33:373-89.
21. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007;57:928-34.
22. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004; 42:649-52.
23. Tisnado DM, Adams JL, Liu H, Damberg CL, Chen WP, Hu FA, et al. What is the concordance between the medical record and patient self-report as data sources for ambulatory care? Med Care 2006;44:132-40.
24. Korthuis PT, Asch S, Mancewicz M, Shapiro MF, Mathews WC, Cunningham WE, et al. Measuring medication: do interviews agree with medical record and pharmacy data? Med Care 2002;40:1270-82.
25. Morand EF, McCloud PI, Littlejohn GO. Continuation of long-term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992;51;1318-21.
26. Guzek J, Guzek S, Murphy K, Gallacher P, Lesneski C. Improving diabetes care using a multitiered quality improvement model. Am J Med Qual 2009;24:505-11.
27. Ansari M, Shlipak MG, Heidenreich PA, van Ostaeyen D, Pohl EC, Browner WS, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation 2003;107:2799-804.